Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

Nephrosis, Lipoid Clinical Trial

Official title:
Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome

Status Completed

Clinical Trial Summary

Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (MCNS).

Clinical Trial Description

This is a prospective, open-label, randomized study in which patients who present for the first time with a clinical diagnosis of idiopathic MCNS proven on renal biopsy will be assigned to either conventional standard-dose prednisolone monotherapy or myfortic combined with low-dose prednisolone treatment for 6 months. Clinical response and relapse rates within 6 months of treatment cessation will be the main outcome parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01185197
Study type	Interventional
Source	The University of Hong Kong
Contact
Status	Completed
Phase	Phase 4
Start date	September 2010
Completion date	June 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05797051` - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Terminated	`NCT04387448` - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Phase 2
Completed	`NCT00577525` - Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome	N/A